Here are 1-2 brief analogies for Mira Pharmaceuticals:

• The Jazz Pharmaceuticals (formerly GW Pharmaceuticals) of next-generation synthetic cannabinoid drugs.

• An early-stage Eli Lilly focused on developing novel synthetic cannabinoid drugs for cognitive decline and pain.

• MIRA1a: An investigational synthetic THC analog being developed for the treatment of anxiety, cognitive decline associated with early-stage dementia, and chronic pain.

Mira Pharmaceuticals (MIRA) is an early pre-clinical-stage pharmaceutical company. At this stage, the company is focused on the research and development of its drug candidate, MIRA1a, and has not yet undergone clinical trials or received FDA approval for commercialization.

Therefore, Mira Pharmaceuticals does not currently have any major customers for its drug products, as it is not yet selling MIRA1a to other companies or directly to individuals.

Erez Aminov was appointed Chief Executive Officer in April 2023. He brings deep expertise in biotechnology consulting, investment, and leadership. Prior to joining MIRA Pharmaceuticals, he founded Locate Venture Corp, where he supported early-stage biotech enterprises and fostered growth through strategic partnerships. He has also served as a trusted consultant for multiple biotech firms and successfully guided two companies through IPOs on the Nasdaq. Additionally, he serves as the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc..

Alan Weichselbaum was appointed Chief Financial Officer effective May 15, 2025. He has over 30 years of experience in corporate finance, capital markets, and strategic advisory. He currently serves as CFO of both MIRA Pharmaceuticals, Inc. and Telomir Pharmaceuticals, Inc. Since 2015, he has been a Director of FinWise Bancorp. In 2011, Mr. Weichselbaum founded The Wexus Group, an outsourced CFO advisory firm. From 1995 to 2010, he held senior roles on Wall Street, including equity analyst, manager of two hedge funds, and CEO of a boutique brokerage firm. His career also includes managerial positions at Philip Morris Capital Corporation and Price Waterhouse.

Dr. Adam Kaplin co-founded MIRA Pharmaceuticals, Inc. in 2020. He is a neuropsychiatrist specializing in the biological basis of immune-mediated depression and cognitive impairment. Previously, he served as the chief neuropsychiatric consultant to the Johns Hopkins Multiple Sclerosis Center of Excellence and was the founder and director of the Johns Hopkins Ketamine Clinic. He has also co-founded other healthcare-related startups, including REWARD Pathways, focused on addiction treatment.

Dr. Itzchak Angel is an accomplished executive with over 40 years of experience in the pharmaceutical industry, guiding medical, pharmaceutical, drug, and business development. Since 2005, he has been President and CEO of Angel Pharmaceutical Consulting & Technologies (A.P.C.T.), assisting various companies in drug development. He previously served as Head of Pharmacology at Synthelabo (now Sanofi-Aventis), where he contributed to the research and development of drugs such as Xatral, Ambien, and Mizollen.

Ned MacPherson currently serves as Chief Growth Officer for Power Digital. From May 2016 to December 2023, he was the CEO and Head of Growth for Endrock Growth & Analytics, a company he founded and subsequently sold to Power Digital. Prior to founding Endrock Growth & Analytics, Mr. MacPherson held senior marketing and leadership positions at companies including sunglass maker Prive Revaux, curated meal company Menud, and Rejuvenetics, LLC.

The primary key risk to Mira Pharmaceuticals is the inherent uncertainty and extensive process of developing its sole drug candidate, MIRA1a, from an early pre-clinical stage through clinical trials to gain regulatory approval. The company's future success is entirely dependent on the successful development, FDA approval, and commercialization of MIRA1a, which faces significant hurdles given that current data is based on pre-clinical and animal studies and does not guarantee success in human trials or eventual market approval.

Mira Pharmaceuticals (MIRA) is developing MIRA1a for the treatment of anxiety, cognitive decline typically associated with early-stage dementia, and chronic pain. The addressable markets for these indications are substantial:

• Anxiety Treatment Market: The global anxiety disorders treatment market is estimated to be approximately USD 11.59 billion in 2024, with projections indicating growth to around USD 15.90 billion by 2032. Another estimate places the global anxiety disorders treatment market at USD 12.33 billion in 2025, expected to reach USD 17.56 billion by 2035. North America held a significant share of the global market in 2025.
• Cognitive Decline (Early-Stage Dementia) Treatment Market: The global dementia treatment market was estimated at USD 18.03 billion in 2024 and is projected to reach USD 28.11 billion by 2030. Similarly, the global dementia treatment market size was valued at USD 19.98 billion in 2025 and is expected to reach USD 38.37 billion by 2033. The U.S. dementia treatment market alone was approximately USD 6,261.6 million in 2024 and is expected to grow to USD 9,290.6 million by 2030. North America consistently holds a significant share of the global market.
• Chronic Pain Treatment Market: The global chronic pain treatment market was valued at approximately USD 84.23 billion in 2024 and is expected to reach USD 132.08 billion by 2030. Other estimates suggest the global market was around USD 90.73 billion in 2024 and is anticipated to reach USD 152.42 billion by 2032. North America represents a significant portion of this market, with one report indicating it held approximately 45% market share in 2024. The U.S. chronic pain management market was valued at USD 31.18 billion in 2025 and is projected to reach USD 42.87 billion by 2034.

Share Issuance

• Mira Pharmaceuticals completed an initial public offering (IPO) in August 2023, pricing 1,275,000 shares of common stock at $7.00 per share, which generated aggregate gross proceeds of $8.9 million.
• In October 2025, the company raised approximately $3,835,485 in gross proceeds by selling 1,751,000 shares of common stock through at-the-market (ATM) block sales to institutional investors at an average price of $2.19 per share.
• The company also financed operations through a private placement of common stock during the fourth quarter of 2021 and throughout 2022.

Inbound Investments

• As part of the acquisition of SKNY Pharmaceuticals in September 2025, SKNY contributed $5 million in marketable securities to Mira Pharmaceuticals, which strengthened MIRA's balance sheet.
• Institutional investors purchased a total of 382,371 shares of MIRA Pharmaceuticals' stock over the two years leading up to February 2026, representing approximately $502.42K in transactions.

Outbound Investments

• Mira Pharmaceuticals completed the acquisition of 100% of SKNY Pharmaceuticals, Inc. in September 2025, in an all-stock transaction. This acquisition expanded MIRA's pipeline to include therapeutic programs such as SKNY-1 for obesity and smoking cessation.

Capital Expenditures

• Information from financial statements, including cash flow statements, indicates that capital expenditures have been consistently reported as "N/A". This is typical for an early-stage biopharmaceutical company primarily focused on research and development activities.